The agency inspected the company’s Cypress, Calif., facility in August, according to a May 25 Securities and Exchange Commission document. iRhythm attempted to correct the issues, but as of May the FDA was not satisfied. The agency alleged “nonconformities to regulations for medical devices, including medical device reporting requirements, relating to the company’s Zio AT System and medical device quality system requirements,” the letter said. The full details of the problem have not yet been released by the FDA.
The warning does not restrict the manufacture and sale of iRhythm’s products and does not require a recall.
“The company takes these matters very seriously,” the letter said. “The company intends to respond within the specified time period and work diligently to address the FDA’s concerns.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.